fashion -WSS

fashion

author：knowledge 2025-09-27 12:35:40 - browse：35775

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： A virus, fished out of a lake, may have saved a man’s life

WSS

Colorectal cancer study finds potential in overlooked immune cell

Pediatric cancer treatments threatened by a new FDA policy

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Flagship Pioneering launches a new biotech in two countries

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Liquid biopsy for lung cancer is launched by Delfi

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Bright Health sells Medicare Advantage business to Molina

Analysis of telehealth claims data suggest service duplication

Hollywood unions extend contract negotiations for actors

Histogen: Failed biotech offers rare public look inside

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

As demand for Covid shots wanes, Moderna seeks its next success

30 years of 'Listening to Prozac'

Moonlake's readout produced a cash windfall. Risks remain

J&J to emphasize cancer drugs, stop much of its vaccine research

entertainment

What to expect at HLTH 2023, the health care industry conference

How to pay for weight loss drugs and save Medicare

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

A virus, fished out of a lake, may have saved a man’s life

VC firm General Catalyst wants to buy a health system

U.K. Biobank has 500,000 peoples' genome sequences available

focus

focus

knowledge

focus